Who
Blaine Davis
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Cartesian Therapeutics; Chief Financial Officer, Protara Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 1
- Sells
- 3
- Bought
- $25K
- Sold
- $278K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Feb 2020
- Last trade
- 6 Jan 2026
- Last filed
- 8 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jan 2026filed 8 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K10,591 at $6.82 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K10,591 at $6.82 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 6 Jan 2025filed 7 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K4,028 at $16.83 | filing |
| 3 Jan 2025filed 7 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K3,961 at $16.72 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,600 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,110,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,424,000 at $0.00 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | $988K1,250,000 at $0.79 | filing |
| 28 Nov 2022filed 30 Nov 2022 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 15 Jul 2022filed 19 Jul 2022 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K5,081 at $3.13 | filing |
| 3 Jan 2022filed 5 Jan 2022 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,800 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,100 at $0.00 | filing |
| 19 Jan 2021filed 21 Jan 2021 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 22 Sep 2020filed 23 Sep 2020 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K1,481 at $16.91 | filing |
| 11 Feb 2020filed 11 Feb 2020 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.